BioSpace News Archive

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the Parent Project Muscular Dystrophy (PPMD) Virtual Annual Conference, which begins Wednesday, July 22, 2020. Joanne Donovan, M.D., Ph.D, Chief Medical Officer of Catabasis,

Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Erik Spek, Ph.D., J.D., has joined the company as Vice President, Legal and Intellectual Property. Dr. Spek is an experienced biotech executive who has been a leader in corporate legal affairs and intellectual property for biotech companies, including Vedant

MDClone, a digital health company, together with leading healthcare organizations from around the world, announced today the founding of The Global Network - a research and knowledge sharing collaborative

Patients Treated with INOpulse® Demonstrated Improved Physical Activity Compared to Placebo Live Webinar with Study Investigators on Thursday, July 16 th , from 4:00-5:00 pm EDT

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has initiated the commercial manufacturing of Gimoti™ (metoclopramide) nasal spray with its manufacturing partner, Patheon, a division of Thermo Fisher Scientific, Inc. Gimoti was approved by the U.S. Food and Drug Administration on June 19, 2020 for the relief of symptoms in adults with a

RaySearch Laboratories AB has entered into a licensing and distribution agreement with TAE Life Sciences, manufacturer of the Alphabeam™ System for boron neutron capture therapy.

Hillrom announced that its board of directors declared a fiscal 2020 fourth quarter dividend of $0.22 per share payable on September 30, 2020, to shareholders of record as of the close of business on September 18, 2020.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces that it will release its financial results for the second quarter 2020 on Wednesday, August 5, 2020.

Leading-edge technologies and platform enhancements speed up collaborative design and expedite product delivery

Applied DNA Sciences Inc. a leader in Polymerase Chain Reaction -based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, announced the appointment of Mr. Sanjay Hurry to Executive Director of Investor Relations and Corporate Communications for the company.